23 Jan 2018
23 Jan 2018
This latest study from the Peter Morris Centre for Evidence in Transplantation highlights that clinical trials of immunosuppressants may well not be representative of the clinical transplant population. This is something that the ESPRIT Group have long warned, especially in terms of generic immunosuppressants.
27 Nov 2017
28 Sep 2017
A complete guide to immunosuppression after organ transplantation and a description of the various different types of immunosuppressant medicines available in the UK
13 Apr 2017
Over the past couple of years a number of alternative forms of immunosuppressant agents have been withdrawn completely, and some reductions made in the range of available dosages. In particular the number of different tacrolimus and mycophenolate mofetil products has been reduced. This has been reflected in the latest ESPRIT tabulation.
04 Jan 2017
The tabulation of comparative bioequivalence data for immunosuppressant products, plus NHS list prices as quoted in the BNF, has been fully updated and data on Envarsus (m/r tacrolimus) added. Please note that contract prices may well vary.
02 Jun 2016
Our appeal against NICE’s proposal to restrict usage of different immunosuppressants has been essentially successful, with nearly 70% of our points of appeal being upheld. An important achievement for transplant patients by the united transplant community. See full decision document from NICE on immunosuppressant usage in adults. The parallel appraisal for immunosuppressants in children was also consistent with this .
05 Apr 2016
The ESPRIT Group appealed against the proposed new NICE recommendations which would restrict usage of certain immunosuppressant agents in transplant patients. We were joined by BTS, BRS, RA, BKPA, NKF, BAPN, NHS England. Decision from NICE within 15 days.
18 Nov 2015
31 Aug 2015